Regulation & Approvals
Recursion Aligns With FDA on Phase 3 Trial Design for REC-4881 in FAP
By News Desk ·
Key takeaways
- Recursion aligned with the FDA on a registrational Phase 3 trial design for REC-4881 in familial adenomatous polyposis.
- The trial's primary endpoint counts excision of adenomas 10 mm or larger in the upper or lower GI tract as an event.
- The randomized, double-blind, placebo-controlled trial is expected to enroll approximately 200 adults and begin in the second half of 2027.
- Updated TUPELO data presented on November 2, 2026 showed a 47% median reduction in total polyp burden after 12 weeks.
Recursion said on November 18, 2026 that it aligned with the FDA on the design of a registrational Phase 3 trial of REC-4881, an oral MEK1/2 inhibitor for familial adenomatous polyposis, a disease with no approved pharmacologic therapies. The GlobeNewswire announcement said the trial is on track to begin in the second half of 2027.
How the REC-4881 Phase 3 Trial Is Designed
Recursion Pharmaceuticals is a clinical-stage company that uses AI and proprietary biological data to discover drugs, with headquarters in Salt Lake City. REC-4881 was identified through unbiased phenotypic screening using Recursion's AI foundation models, and the company said it is among the first AI-enabled programs to advance a registrational Phase 3 trial design for a disease with no approved pharmacologic therapies.
The trial is a randomized, double-blind, placebo-controlled, event-driven study expected to enroll approximately 200 patients aged 18 and older who have had a colectomy or proctocolectomy. It will evaluate REC-4881 at a dose of 4 mg, with the dosing schedule to be determined from data emerging from the ongoing TUPELO trial, and will include a prespecified interim analysis.
The primary endpoint is event-free survival, counting the excision of an adenoma 10 mm or larger in either the upper or lower GI tract, prespecified criteria for multiple types of FAP-related surgery, high-grade dysplasia or cancer, or death from any cause. Modified Spigelman stage progression and total polyp burden are secondary endpoints.
"Securing FDA alignment on a novel component of our primary endpoint - counting the removal of adenomas 10 mm or larger across both the upper and lower GI tract as events - is a key milestone," said Najat Khan, Ph.D., President and Chief Executive Officer of Recursion.
Recursion's Funding and Leadership Record
Recursion appointed Najat Khan as CEO and President effective January 1, 2026, with co-founder Chris Gibson moving to Chairman, according to akta.pro company records. The same records show a $200 million post-IPO equity round in October 2026 and a completed $688 million merger with Exscientia in November 2024, followed by a workforce reduction of about 20% to integrate operations.
Earlier REC-4881 Results and Board Change
On November 2, 2026, Recursion reported Phase 2 results for REC-4881 showing a 47% median reduction in total polyp burden after 12 weeks, Investing.com reported. The updated TUPELO data presented at CGA-IGC that day showed approximately 1 in 3 patients achieving reductions of 65% or more, with no new safety signals.
Recursion appointed Fred Hassan as Chair of its Board effective October 31, 2026, GlobeNewswire reported, citing his four decades of pharmaceutical leadership including roles at Schering-Plough and Pharmacia.
When the Phase 3 Trial Starts
The registrational Phase 3 trial is expected to begin in the second half of 2027, with enrollment of approximately 200 adults with FAP following colectomy or proctocolectomy.